GSK461364 - Small Molecule (ID:10013-101)
HMS LINCS ID: | 10013-101 |
Name: | GSK461364 |
Alternative Names: | GSK461364A |
LINCS ID: | LSM-1013 |
PubChem CID: | 15983966 |
ChEBI ID: | |
ChEMBL ID: | |
Molecular Mass: | 543.19 |
InChi: | InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1 |
InChi Key: | ZHJGWYRLJUCMRT-QGZVFWFLSA-N |
SMILES: | C[C@H](C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N |
Relevant Citations: | |
Comments: | |
Date Publicly Available: | |
Most Recent Update: | 2016-05-06 |
Target Affinity:
(see Study 20000)Target Affinity Spectrum Value | HUGO Gene Name |
---|---|
NUAK2, PLK1, STK10 | |
2 (equivalent to 100 nM ≤ Kd < 1µM) | BMP2K, CAMK2D, CSNK2A2, FLT3, NEK2, PIM1, PIP5K1A, PKN2, PLK2, PLK3, RPS6KA3, RPS6KA4, RPS6KA6 |
3 (equivalent to 1µM ≤ Kd < 10 µM) | ANKK1, BRSK2, CAMK2A, CAMK2B, CAMK2G, CDK7, CSNK2A1, DAPK1, DAPK2, DAPK3, EIF2AK4, GRK4, GRK7, IRAK1, IRAK3, KIT, MAP3K1, MAP3K19, MAP3K9, MAP4K2, MERTK, NEK1, NEK5, NEK8, NEK9, NIM1K, PDGFRB, PIK3C2B, PIK3CB, PIK3CD, PIK3CG, PIM3, PIP4K2B, PIP5K1C, PRKCD, PRKCI, PRKD3, RIOK1, RIOK3, ROCK1, RPS6KA2, SLK, SRPK3, TAOK3, TIE1, ULK2 |
10 (confirmed non-binding) |
Datasets:
HMS Dataset ID | Dataset Title | HMS Dataset Type |
---|---|---|
20000 | Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library. | Analysis |
20031 | GSK461364 KINOMEscan | KINOMEscan |
20120 | Metrics other than potency reveal systematic variation in responses to cancer drugs | Analysis |
20268 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. | Analysis |
20269 | Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. | Analysis |
20270 | Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. | Analysis |
KINOMEscan Image
Batch Information:
HMS LINCS Batch ID | Provider | Provider Batch ID |
---|---|---|
10013-101-1 | Haoyuan chemexpress | HM-074_20-20101221 |
10013-101-2 | Haoyuan chemexpress | |
10013-101-3 |
(Kd <100 nM)